AI Verdict
MBLY has stronger fundamentals based on our AI analysis.
MBOT vs MBLY Fundamental Comparison
| Metric | MBOT | MBLY |
|---|---|---|
| Revenue | $2,000.0 | $1.9B |
| Net Income | $-13.1M | $-392.0M |
| Net Margin | -657,100.0% | -20.7% |
| ROE | -16.9% | -3.3% |
| ROA | -16.1% | -3.1% |
| Current Ratio | 23.33x | 6.10x |
| Debt/Equity | 0.03x | 0.00x |
| EPS | $-0.29 | $-0.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MBOT vs MBLY: Frequently Asked Questions
Is MBOT or MBLY a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MBLY has stronger fundamentals. MBOT is rated STRONG SELL (95% confidence) while MBLY is rated HOLD (62% confidence). This is not investment advice.
How does MBOT compare to MBLY fundamentally?
Microbot Medical Inc. has ROE of -16.9% vs Mobileye Global Inc.'s -3.3%. Net margins are -657,100.0% vs -20.7% respectively.
Which stock pays higher dividends, MBOT or MBLY?
MBOT has a dividend yield of N/A or no dividend while MBLY has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MBOT or MBLY for long term?
For long-term investing, consider that MBOT has STRONG SELL rating with 95% confidence, while MBLY has HOLD rating with 62% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MBOT vs MBLY?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MBOT vs MBLY, the AI consensus favors MBLY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.